Your browser doesn't support javascript.
loading
Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.
Beckman, Joan D; Rollins-Raval, Marian A; Raval, Jay S; Park, Yara A; Mazepa, Marshall; Ma, Alice.
Afiliación
  • Beckman JD; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC.
  • Rollins-Raval MA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
  • Raval JS; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
  • Park YA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
  • Mazepa M; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
  • Ma A; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC.
Am J Ther ; 25(2): e270-e272, 2018.
Article en En | MEDLINE | ID: mdl-29293474
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Púrpura Trombocitopénica Idiopática / Inhibidores de Proteasoma / Bortezomib Límite: Female / Humans / Middle aged Idioma: En Revista: Am J Ther Asunto de la revista: TERAPEUTICA Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Púrpura Trombocitopénica Idiopática / Inhibidores de Proteasoma / Bortezomib Límite: Female / Humans / Middle aged Idioma: En Revista: Am J Ther Asunto de la revista: TERAPEUTICA Año: 2018 Tipo del documento: Article